- Evotec’s biologics segment expands its partnership with Sandoz for developing and commercially manufacturing biosimilars.
- The collaboration includes long-term supply guarantees and additional potential biosimilars for Sandoz’s pipeline.
Just – Evotec Biologics has expanded its strategic partnership with Sandoz to develop and commercially manufacture biosimilars. The expanded agreement, announced on 8 July 2024, includes appropriate remuneration for early scientific validation and further funding tied to achieving development milestones from 2025.
The collaboration solidifies Just – Evotec Biologics’ commitment to providing long-term commercial supply of biosimilars to Sandoz from its newly built J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. Sandoz will benefit from significant commercial manufacturing capacity to ensure a steady supply of biosimilars for patients.
Since May 2023, Just – Evotec Biologics and Sandoz have been engaged in a multi-year technology partnership aimed at the rapid development and manufacturing of biosimilars. This partnership leverages Just – Evotec Biologics’ data-driven, fully integrated design capability and continuous manufacturing technology platform (J.DESIGN) to deliver high product quality and cost efficiency.
Dr Matthias Evers, Chief Business Officer of Evotec, stated, “We are thrilled to expand our partnership with Sandoz, building on the successes we’ve achieved since the initial launch. Introducing additional molecules has the potential to enhance access for millions of patients, while commercial manufacturing from Toulouse will ensure the long-term supply of Sandoz’ biosimilar portfolio.”
Overview of outsourcing trends 
